Related Experiment Videos
Danazol-induced hypercalcaemia in alphacalcidol-treated hypoparathyroidism
N C Hepburn1, L A Abdul-Aziz, R Whiteoak
1Department of Medicine, British Military Hospital, Rinteln.
Postgraduate Medical Journal
|November 1, 1989
Summary
Idiopathic hypoparathyroidism patients on alphacalcidol may develop hypercalcemia when treated with danazol for endometriosis. This case highlights potential drug interactions in managing complex endocrine conditions.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Idiopathic hypoparathyroidism is a rare endocrine disorder characterized by insufficient parathyroid hormone production.
- Patients often require lifelong treatment with vitamin D analogs, such as alphacalcidol, to maintain calcium homeostasis.
Observation:
- A patient with idiopathic hypoparathyroidism, successfully managed with alphacalcidol, was prescribed danazol for endometriosis.
- Following the initiation of danazol therapy, the patient presented with symptomatic hypercalcemia.
Findings:
- The concurrent use of alphacalcidol and danazol led to clinically significant hypercalcemia.
- This suggests a potential pharmacodynamic or pharmacokinetic interaction between the two medications.
Implications:
- Clinicians should exercise caution when prescribing danazol to patients with hypoparathyroidism on vitamin D therapy.
- Monitoring serum calcium levels is crucial during combined treatment to prevent or manage hypercalcemia.
- Further research may be warranted to elucidate the exact mechanism of this drug interaction.